Articles

  1. Research

    Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

    Eolia Brissot, Myriam Labopin, Matthias Stelljes, Gerhard Ehninger, Rainer Schwerdtfeger, Jürgen Finke, Hans-Jochem Kolb, Arnold Ganser, Kerstin Schäfer-Eckart, Axel R. Zander, Donald Bunjes, Stephan Mielke, Wolfgang A. Bethge, Noël Milpied, Peter Kalhs, Igor-Woflgang Blau…

    Published on: 24 June 2017

  2. Research

    Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos…

    Published on: 20 June 2017

View all articles

View all articles

Aims and scope

Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology.

Editor's quote

"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."

Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology

Experimental Hematology & Oncology

Submit your research to our companion journal, Experimental Hematology & Oncology

Research highlights

Journal of Hematology & Oncology is now publishing Research Highlights, commentaries on recently published work that place the new research in the context of the current literature.

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
Janice Lu

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
Gaurav Goel, Weijing Sun

Advertisement

JHO logo

Advertisement